Physician profile
Jigar Patel
NPI 1841654316
$2,014.32
in general payments reported to CMS, 2019-2025
14 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.35 · 2021: $37.66 · 2022: $147 · 2023: $580 · 2024: $802 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,786 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.87 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.20 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $510.01 | 2022-2025 | Ilumya, Odomzo |
| E.R. Squibb & Sons, L.L.C. | $298.15 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $129.01 | 2022-2025 | Libtayo |
| Leo Pharma INC. | $92.71 | 2023-2024 | Adbry |
| Arcutis Biotherapeutics, INC. | $81.39 | 2024-2025 | Zoryve |
| Organon LLC | $56.20 | 2025 | Vtama |
| Organogenesis INC. | $45.62 | 2023-2024 | Affinity, Puraply |
| Dermavant Sciences, INC. | $44.62 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $32.18 | 2023 | Tremfya |
| Incyte Corporation | $28.08 | 2023 | Opzelura |
| Ucb, INC. | $28.00 | 2025 | Bimzelx |
| Genzyme Corporation | $21.53 | 2023 | |
| Galderma Laboratories, L.P. | $19.62 | 2024 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.